In prescribing to patients as a rule of thumb, it is often useful to remember the “Rule of Thirds.” Specifically, 1/3 of patients treated will have a complete remission of symptoms; 1/3 of patients will have a partial remission; and 1/3 of patients will not obtain any treatment effect. Hence, prescribers are commonly faced with conditions such as Treatment Resistant Depression or Treatment Resistant Schizophrenia. Innovations in drug development or formulation often signifies new treatment options for patients through bioengineering and addressing new mechanisms of action to produce treatment effects. The Federal Drug Administration (FDA) is entrusted with guiding and evaluating new drug development in accordance with manufacturing and clinical trial requirements, human safety, along with other data needed for FDA approval.

In this presentation Dr. Lynette Pujol will review new FDA medications approved in 2023 and review new research findings in psychopharmacology. Mechanisms of action, approved indications, dosages, serious and common side-effects and CYP 450 interactions will be presented. Why the new drug might be used clinically over others on the market will also be discussed. New research directions will be presented, including clinical trials and drugs in development.

Click here to view full course information: